



FOR IMMEDIATE POSTING

CONTACT:

Virginia Bader, 703-963-9906

vbader@gymr.com

Genevieve Matthews, 858-699-9187

gfmattthews@ucsd.edu

Researchers presented results of a study of a computerized assessment tool of memory function that strongly correlate to results from tests traditionally administered on paper in a clinical setting.

Novel Cognitive Outcomes for Preclinical Alzheimer's Disease Prevention Trials

Presenters/Authors: Dorene M. Rentz, PsyD, Harvard Medical School in the Departments of Neurology at Brigham and Women's Hospital and Massachusetts General Hospital, Boston, MA

About: Dr. Rentz and colleagues reported clinical outcome measures that are sensitive to the earliest cognitive decline during the preclinical phase of stages of Alzheimer's disease (AD). This data is providing early validation for use in upcoming preclinical AD prevention trials. The group also reported a novel iPad computerized composite demonstrating a strong correlation with standard neuropsychological tests, particularly across memory measures, supporting the introduction of computerized measures into preclinical AD trials.

###

About CTAD

Since 2008, CTAD has been a conference organized and planned by Alzheimer's disease (AD) clinical researchers for AD clinical researchers. CTAD embraces the organizing committee mandate to maintain CTAD's unique role in AD research: To provide a substantive, clinical research-oriented conference and an annual opportunity for the world's preeminent clinical researchers to engage in both formal and informal exchanges of views. CTAD's ongoing commitment to providing a relatively intimate forum has resulted in the conference's reputation of facilitating and fostering international collaboration in AD clinical research matters. More information is available at www.ctad.fr/.

**Reporting on all studies is under embargo until the time of presentation.
See the full program at www.ctad.fr/.**